Pancreatic cancer ranks amongst the most aggressive, incurable cancer diseases. While recently developed immunotherapies provided a breakthrough for treatment of several solid tumors, clinical trials failed for pancreatic cancer. Therefore, the complex composition of pancreatic cancer immune infiltrates was dissected in genetically engineered mouse models revealing a lack of adaptive anti-tumor immunity but prominent accumulation of myeloid immune suppressors. Notch activation, however, was found to provide a promising target to reprogram tumor-associated macrophages to a more favorable anti-tumor phenotype.
«
Pancreatic cancer ranks amongst the most aggressive, incurable cancer diseases. While recently developed immunotherapies provided a breakthrough for treatment of several solid tumors, clinical trials failed for pancreatic cancer. Therefore, the complex composition of pancreatic cancer immune infiltrates was dissected in genetically engineered mouse models revealing a lack of adaptive anti-tumor immunity but prominent accumulation of myeloid immune suppressors. Notch activation, however, was foun...
»